CD274 and neoplasm: Some therapeutic molecules, including chemotherapeutics and anti-PD-L1 antibodies, can be delivered to and released within tumor cells or TME via ROS-responsive prodrugs or nanoparticles, thereby inhibiting tumor cell growth in vitro and in vivo [287–289].